TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32416231

Group type: EXPERIMENTAL
Intervention: Aliviado Dementia Care-Hospice Edition training program
Number of subjects: 53

Group type: COMPARATOR
Intervention: Pre-training assessment
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Post-training assessment
Number of subjects: 53
Study: 32416264

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasonography for sliding sign testing
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Negative sliding sign and EFI historic factors score
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Negative sliding sign with diagnosis of endometrioma
Number of subjects: 86
Study: 32416715

Group type: EXPERIMENTAL
Intervention: Osteoarthritis Physical activity Care Pathway (OA-PCP) intervention involving 3 physical activity coaching calls, three check-in emails, and linkage with community resources.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Osteoarthritis Physical activity Care Pathway (OA-PCP) intervention
Number of subjects: 60
Study: 32416765

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32416764

Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800CW 25 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800CW 50 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800CW 75 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800CW (all doses)
Number of subjects: 11
Study: 32417327

Group type: EXPERIMENTAL
Intervention: Multimodality imaging
Number of subjects: 0
Study: 32417333

Group type: EXPERIMENTAL
Intervention: Active AL amyloidosis with cardiac involvement (active-CA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Active AL amyloidosis without cardiac involvement (active-non-CA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AL amyloidosis with cardiac involvement in remission (remission-CA)
Number of subjects: 45
Study: 32417337

Group type: EXPERIMENTAL
Intervention: Stress cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate x-ray coronary angiography (XCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-photon emission computed tomography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary computed tomographic angiography with selective computed tomographic fractional flow reserve
Number of subjects: 0
Study: 32417369

Group type: EXPERIMENTAL
Intervention: FGFR3 genomic alterations (GAs)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: High FGFR3 activity
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: lncRNA-FGFR3-active tumors
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: High FGFR3 gene expression
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: FGFR3 activity or mutation/fusion
Number of subjects: 112
Study: 32417405

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 34
Study: 32417537

Group type: EXPERIMENTAL
Intervention: Asfotase alfa (enzyme replacement therapy)
Number of subjects: 19
Study: 32417924

Group type: EXPERIMENTAL
Intervention: Pulmonary portal of entry
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: iha_17 virulence gene
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: STc88
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Healthcare-associated infections
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: High Charlson comorbidity index
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 545
Study: 32418049

Group type: EXPERIMENTAL
Intervention: Scalp block
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (traditional pharmacological approach)
Number of subjects: 13
Study: 32418051

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (BRAF+ subgroup)
Number of subjects: 0
Study: 32418142

Group type: EXPERIMENTAL
Intervention: < 12-month DAPT
Number of subjects: 2967

Group type: COMPARATOR
Intervention: ≥ 12-month DAPT
Number of subjects: 2967
Study: 32418251

Group type: EXPERIMENTAL
Intervention: Faecal calprotectin measurement by ELISA
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Faecal calprotectin measurement by immunochromatography
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Comparison of species diversity and relative bacterial abundance profiles
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Prognostic score of enteropathy
Number of subjects: 121
Study: 32418478

Group type: EXPERIMENTAL
Intervention: Comorbidity index (sum of 14 noncardiac conditions)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Depression alone
Number of subjects: 373

Group type: COMPARATOR
Intervention: Noncardiac comorbidities (other than depression)
Number of subjects: 373
Study: 32418493

Group type: EXPERIMENTAL
Intervention: SCD risk prediction model
Number of subjects: 572
Study: 32418613

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 32418720

Group type: EXPERIMENTAL
Intervention: SVEAT score
Number of subjects: 321

Group type: COMPARATOR
Intervention: HEART score
Number of subjects: 321

Group type: COMPARATOR
Intervention: TIMI score
Number of subjects: 321
Study: 32418717

Group type: EXPERIMENTAL
Intervention: COMBO biodegradable polymer sirolimus-eluting stent
Number of subjects: 2614
Study: 32418771

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 72
Study: 32418789

Group type: EXPERIMENTAL
Intervention: PCV13 vaccination (3 doses with a minimum of 1 month interval between treatment courses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 36
Study: 32418803

Group type: EXPERIMENTAL
Intervention: Substituting prolonged sedentary time for sleep
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Substituting total or prolonged sedentary for moderate-to-vigorous physical activity
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Substituting total or prolonged sedentary for light physical activity
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Substituting prolonged sedentary for short bouts
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Substituting total or prolonged sedentary with light physical activity
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Substituting with moderate-to-vigorous physical activity
Number of subjects: 423
Study: 32418854

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 318

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention
Number of subjects: 318

Group type: COMPARATOR
Intervention: Angiographic presentation as intramural hematoma
Number of subjects: 318
Study: 32419399

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 345
Study: 32419586

Group type: EXPERIMENTAL
Intervention: Continuation of antiplatelet therapy (APT) during noncardiac surgery
Number of subjects: 3582

Group type: COMPARATOR
Intervention: Discontinuation of antiplatelet therapy (APT) during noncardiac surgery
Number of subjects: 3582
Study: 32419679

Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/day, escalated to 80 mg/day after week 4 based on tolerability and clinical assessment of TD.
Number of subjects: 161
Study: 32419820

Group type: EXPERIMENTAL
Intervention: Acupuncture group (AG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Electroacupuncture group (EG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham group (SG)
Number of subjects: 45
Study: 32419949

Group type: EXPERIMENTAL
Intervention: Combined bowel preparation (2L polyethylene glycol solution night before CE, 5mL simethicone and 5mg metoclopramide 20 minutes prior to CE, right lateral position 30 minutes after swallowing CE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no solid food after 7 p.m. night prior to CE, no liquids 4 hours prior to CE)
Number of subjects: 50
Study: 32419950

Group type: EXPERIMENTAL
Intervention: Device-based physical activity in Swedish participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Device-based physical activity in Australian participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour in both countries
Number of subjects: 0
Study: 32420402

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 302

Group type: COMPARATOR
Intervention: Artemisinin-based combination therapies
Number of subjects: 302
Study: 32420450

Group type: EXPERIMENTAL
Intervention: Conventional compression factor (CCF, 0.75 D)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Increased compression factor (ICF, 1.75 D)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (spectacle-wearing)
Number of subjects: 99
Study: 32420697

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 42
Study: 32421208

Group type: COMPARATOR
Intervention: Pharmacological galactagogues (domperidone, metoclopramide, sulpiride, thyrotropin-releasing hormone)
Number of subjects: 3005

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 3005

Group type: COMPARATOR
Intervention: Natural galactagogues (banana flower, fennel, fenugreek, ginger, ixbut, levant cotton, moringa, palm dates, pork knuckle, shatavari, silymarin, torbangun leaves or other natural mixtures)
Number of subjects: 3005

Group type: COMPARATOR
Intervention: Natural galactagogues
Number of subjects: 3005
Study: 32421437

Group type: EXPERIMENTAL
Intervention: De novo LQTS variants (especially SCN5A variants)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Familial LQTS variants
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Premature ventricular contractions
Number of subjects: 39
Study: 32422174

Group type: EXPERIMENTAL
Intervention: Static fixation test
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 30sEpoch dynamic fixation test
Number of subjects: 235
Study: 32422241

Group type: EXPERIMENTAL
Intervention: ECG-gated coronary computed tomography angiography (CCTA)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CCTA considering non-evaluable segments as obstructive
Number of subjects: 104
Study: 32423317

Group type: EXPERIMENTAL
Intervention: AF-ESUS score (integer-based point scoring system)
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Score of ≤0
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Area under the curve of the score
Number of subjects: 839
Study: 32423376

Group type: EXPERIMENTAL
Intervention: Platelet to lymphocyte ratio (PLR) > 204.4
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Neutrophil to lymphocyte ratio (NLR) > 3.1
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: NLR combined with hs-cTnT or NT-proBNP
Number of subjects: 38

Group type: COMPARATOR
Intervention: Patients with MACCE
Number of subjects: 38
Study: 32423402

Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Prenatal diagnosis
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Postpartum depression scores (EPDS)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Social withdrawal behaviors (ADBB)
Number of subjects: 158
Study: 32423455

Group type: EXPERIMENTAL
Intervention: Methotrexate and cytosine arabinoside (MA)
Number of subjects: 36
Study: 32423456

Group type: EXPERIMENTAL
Intervention: 0.55 T CMR imaging
Number of subjects: 65

Group type: COMPARATOR
Intervention: 1.5 T CMR imaging
Number of subjects: 65
Study: 32423477

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with epirubicin/docetaxel for 6 cycles, supplemented with bevacizumab in cycles 3-6
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cell-loss metric based on serum thymidine kinase 1 (sTK1) levels
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Tumour volume measurement
Number of subjects: 104
Study: 32423837

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200mg intravenously every 3 weeks until confirmed progression, intolerable toxicity, patient withdrawal, or 24 months of therapy.
Number of subjects: 678
Study: 32423904

Group type: EXPERIMENTAL
Intervention: Sleep apnoea group (defined as apnoea-hypopnoea index ≥15 events per hour)
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Non-sleep apnoea group
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Sleep apnoea group
Number of subjects: 1007
Study: 32423938

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 0
Study: 32424011

Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures (SS-CF) trial
Number of subjects: 1913

Group type: EXPERIMENTAL
Intervention: CHANGE trial
Number of subjects: 1913

Group type: EXPERIMENTAL
Intervention: Indashyikirwa
Number of subjects: 1913
Study: 32424028

Group type: EXPERIMENTAL
Intervention: Antimalarial treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no antimalarial treatment)
Number of subjects: 0
Study: 32424516

Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 0
Study: 32424535

Group type: EXPERIMENTAL
Intervention: NAC-treated graft (N-acetylcysteine enriched tumescent fluid)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control graft (standard tumescent fluid)
Number of subjects: 15
Study: 32425736

Group type: EXPERIMENTAL
Intervention: GBCK25 (500 mg/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: GBCK25 (125 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 32425802

Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg/day
Number of subjects: 40
Study: 32425873

Group type: EXPERIMENTAL
Intervention: iPad-Based App (Neolexon®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32425926

Group type: EXPERIMENTAL
Intervention: T cell-based immunotherapy targeting alpha-fetoprotein (AFP)
Number of subjects: 0
Study: 32426038

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32426039

Group type: EXPERIMENTAL
Intervention: DMF 240 mg twice daily (BID)
Number of subjects: 1736

Group type: COMPARATOR
Intervention: PBO/DMF (placebo for years 0-2 / DMF for years 3-9)
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: DMF/DMF
Number of subjects: 1736

Group type: COMPARATOR
Intervention: PBO/DMF
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: DMF
Number of subjects: 1736
Study: 32426103

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (PC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sphingomyelin (SM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acylcarnitine metabolomes
Number of subjects: 0
Study: 32426158

Group type: EXPERIMENTAL
Intervention: IDEAs (Improving Diabetes Eye screening Attendance) intervention delivered in general practice.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (standard care in general practice).
Number of subjects: 8
Study: 32426309

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32426409

Group type: EXPERIMENTAL
Intervention: Early Controlled Motion (ECM) - ankle movements 5 times a day from weeks 3 to 8 after rupture
Number of subjects: 130

Group type: COMPARATOR
Intervention: Immobilization (IM) - immobilized for 8 weeks
Number of subjects: 130
Study: 32426530

Group type: EXPERIMENTAL
Intervention: Continuous Neonatal Temperature Monitor (NTM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Philips Intellivue MP30 Patient Monitor
Number of subjects: 39

Group type: COMPARATOR
Intervention: Axillary thermometer
Number of subjects: 39
Study: 32427039

Group type: EXPERIMENTAL
Intervention: Isolated atrial septal defect (n=34)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isolated ventricular septal defect (n=32)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy matched peers (n=40)
Number of subjects: 66
Study: 32427279

Group type: EXPERIMENTAL
Intervention: Early corticosteroid (methylprednisolone 0.5 to 1 mg/kg/day for 3 days)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Early corticosteroid
Number of subjects: 213
Study: 32427581

Group type: EXPERIMENTAL
Intervention: IgG antibodies against CIDRα1.7 and CIDRα1.8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IgG antibodies against CIDRγ3
Number of subjects: 0
Study: 32427579

Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1 therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-PD-1 therapy
Number of subjects: 0
Study: 32428300

Group type: EXPERIMENTAL
Intervention: Reducing saturated fat intake
Number of subjects: 59000
Study: 32428369

Group type: EXPERIMENTAL
Intervention: Susceptibility-guided therapy (14-day triple or quadruple therapy based on susceptibility to clarithromycin, levofloxacin, and metronidazole)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: All regimens of susceptibility-guided therapy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Susceptibility-guided therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Empiric classical bismuth quadruple therapy
Number of subjects: 112
Study: 32428543

Group type: EXPERIMENTAL
Intervention: Nitric Oxide-Releasing Topical Medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32429000

Group type: EXPERIMENTAL
Intervention: Gepotidacin 750 mg IV over 2 hours
Number of subjects: 0
Study: 32429847

Group type: EXPERIMENTAL
Intervention: Subretinal drusenoid deposits and drusen
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: RPE cell bodies
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Choriocapillaris' vascular density
Number of subjects: 480
Study: 32429877

Group type: EXPERIMENTAL
Intervention: Integrated services for depression and NCDs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Provider communication strategies
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Training for providers
Number of subjects: 20
Study: 32429879

Group type: EXPERIMENTAL
Intervention: Home-based couple testing during pregnancy
Number of subjects: 21
Study: 32429923

Group type: COMPARATOR
Intervention: Untreated lead-in period (4 months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 4-stair climb timed function measure
Number of subjects: 19

Group type: COMPARATOR
Intervention: Whole-body MRI and DEXA estimates
Number of subjects: 19
Study: 32429929

Group type: EXPERIMENTAL
Intervention: NAC
Number of subjects: 24
Study: 32429939

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy for BDD
Number of subjects: 88
Study: 32429963

Group type: EXPERIMENTAL
Intervention: Selective neural electrical stimulation of radial and median nerves using multicontact cuff electrodes.
Number of subjects: 8
Study: 32429967

Group type: EXPERIMENTAL
Intervention: lenalidomide combined with dexamethasone
Number of subjects: 41
Study: 32430018

Group type: EXPERIMENTAL
Intervention: Chia supplementation (25 g/day)
Number of subjects: 25
Study: 32430019

Group type: EXPERIMENTAL
Intervention: FACT-M questionnaire in treatment-naïve patients (Part B)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: FACT-M questionnaire in previously treated patients (Part A)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Combined FACT-M data from Part A and Part B
Number of subjects: 172

Group type: COMPARATOR
Intervention: ECOG performance status 0 versus 1
Number of subjects: 172

Group type: COMPARATOR
Intervention: EQ-5D items
Number of subjects: 172

Group type: COMPARATOR
Intervention: Cronbach's α
Number of subjects: 172
Study: 32430047

Group type: EXPERIMENTAL
Intervention: BetterBack Model of Care implementation
Number of subjects: 116
Study: 32430177

Group type: EXPERIMENTAL
Intervention: rAAV-G6PC-S298C vector
Number of subjects: 0
Study: 32430395

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9 mg/kg of body weight)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study: 32430412

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 0
Study: 32430414

Group type: EXPERIMENTAL
Intervention: Extrafine triple therapy
Number of subjects: 0
Study: 32430416

Group type: EXPERIMENTAL
Intervention: Home telemonitoring of variability in forced oscillation technique (FOT) measures
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Daily FOT parameters (resistance (R) and reactance (X))
Number of subjects: 15
Study: 32430415

Group type: EXPERIMENTAL
Intervention: Microbiome-based therapies; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Host-targeted therapeutics; details on dosage and duration not available.
Number of subjects: 0
Study: 32430445

Group type: EXPERIMENTAL
Intervention: Patient decision aid
Number of subjects: 772

Group type: COMPARATOR
Intervention: Traditional booklet (Control)
Number of subjects: 772
Study: 32430583

Group type: EXPERIMENTAL
Intervention: Folic polyglutamate tablets (oral) and 500 mL of a 10% mannitol solution (intravenous) before the injection of 3.7-5.5 GBq of radioligand therapy (RLT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Radioligand therapy (RLT) with 3.7-5.5 GBq
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dosimetry measurements
Number of subjects: 43
Study: 32430709

Group type: EXPERIMENTAL
Intervention: 50 g OGTT
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 g OGTT
Number of subjects: 100
Study: 32431021

Group type: EXPERIMENTAL
Intervention: V-LAP™ device
Number of subjects: 0
Study: 32431658

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) paired with aerobic exercise (2.5 mA for 20 minutes)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham tDCS paired with aerobic exercise
Number of subjects: 17
Study: 32431667

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day)
Number of subjects: 0
Study: 32431698

Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval exercise training (HIIT) for 10 weeks, 3 sessions/week, consisting of ten 60 s intervals of low intensity (50-60% HRR) and high intensity (80-90% HRR)
Number of subjects: 10
Study: 32432123

Group type: EXPERIMENTAL
Intervention: Intraperitoneal Fosfomycin, Metronidazole, and Molgramostim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0